Share

Hemophilia therapy update: New information on investigational Factor VIII therapy development

Hemophilia Therapy Update: New Information on Investigational Factor VIII Therapy Development

Monday, December 9, 2002
12:30 – 1:30 EST
Loews Philadelphia Hotel, Commonwealth Hall A

AGENDA

Understanding Treatment Choices – A Father's Perspective
Joe Caronna, Vice President, New Jersey Hemophilia Association, and Father of Patient with Hemophilia A

The Current Hemophilia Treatment Landscape
W. Keith Hoots, M.D., Medical Director, Gulf States Hemophilia and Thrombophilia Center, Houston, Texas

Phase II-III Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) Clinical Trial Data
Peter Collins, M.D., M.R.C.P., Director, Arthur Bloom Haemophilia Centre, University Hospital of Wales, Cardiff, Wales

New Developments in Recombinant Factor VIII Technology
Edward D. Gomperts, M.D., Global Vice President, Medical Affairs, Baxter BioScience

Moderator: Edward D. Gomperts, M.D.

To register for the live webcast, please enter the newsroom of Baxter.com (http://www.baxter.com) and click on the "Hemophilia Therapy Update Webcast" button.

To R.SV.P. for the briefing or to receive additional information, please contact:
Nicole Christopher at 212-601-8279 or nchristopher@porternovelli.com
Sherry Marks at 212-601-8385 or smarks@porternovelli.com

Share

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.